There are an increasing number of molecular assays being developed to guide patient treatments. There is , however, often a limited amount of material available for analysis. Almac Diagnostics have therefore developed DNA and mRNA next generation sequencing based panels that have been analytically validated to deliver multiple Biomarkers from small amounts of material. An associated comprehensive patient report has been developed to guide the best treatment in oncology trials and eventually in standard clinical practice.
During his presentation at Pathology Horizons 2018 Prof. Kennedy will discuss the challenges to implementing these kind of Biomarker panels in clinical care and how these are being overcome.
Prof. Richard Kennedy is the Medical Director and Global VP of Biomarker Development at Almac Diagnostics and the McClay Professor in Medical Oncology at the Centre for Cancer Research and Cell Biology, Queen’s University of Belfast.
Why attend Pathology Horizons?
The conference is set to be another interesting and extremely informative event with a range of top international speakers demonstrating the power of new technologies, updates on procedural developments and valuable new lines of research – all in a relaxed and open atmosphere! Unlike other larger pathology events, Pathology Horizons is a boutique conference with one conference stream, which allows you to interact and network fully with the delegates and speakers. The conference is also CPD certified and has been awarded with 9 CPD credits by The Royal College of Pathologists.
Other topics from speakers include:
- Artificial intelligence and what it means for healthcare
- Liquid biopsy and what it can do for detecting/treating ovarian cancer
- Virtual and augmented reality in digital pathology
- Radiology and pathology integration
- Genome sequencing as a diagnostic aid
Don’t miss out, secure your place today!
Pathology Horizons 2018 Lough Erne Resort, N. Ireland 13-15th September